TP53 and neoplasm: Comparing to the saline control group, dtEVs carrying TP53-mRNA and siKRASG12D suppressed the orthotopic tumor burden after two-week treatment, and adding siGli1 in dtEVsGli1 could further slowdown the orthotopic tumor growth (Fig. 8b and Supplementary Fig. 25).